Beyfortus
Payments companies reported to CMS as associated with Beyfortus. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Beyfortus, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Beyfortus
These are the largest totals companies reported as associated with Beyfortus. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Joseph Domachowske | Syracuse, NY | Pediatric Infectious Diseases | $157,437.81 |
| Christopher Belcher | Carmel, IN | Pediatric Infectious Diseases | $104,618.06 |
| Jaime Fergie | Corpus Christi, TX | Pediatric Infectious Diseases | $77,150.02 |
| David Nelson | Washington, DC | Pediatrics | $57,690.17 |
| Henry Wojtczak | Albuquerque, NM | Pediatric Pulmonology | $56,699.54 |
| Scott Wexelblatt | Cincinnati, OH | Pediatrics | $56,667.99 |
| Todd Ellerin | Boston, MA | Infectious Disease | $54,472.37 |
| Floyd Livingston | Orlando, FL | Pediatric Pulmonology | $52,131.09 |
| Janak Patel | Galveston, TX | Pediatric Infectious Diseases | $51,535.30 |
| Boris Skurkovich | Providence, RI | Pediatrics | $42,663.49 |
Prescribed Beyfortus?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.